Evolutionary Tree Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Evolutionary Tree Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-47,406	Closed	-$553K	–	30
2024 Q4	$553K	Buy	47,406 +12,034	+34%	+$188K	0.56%	29
2024 Q3	$727K	Sell	35,372 -890	-2%	-$20.5K	0.73%	28
2024 Q2	$812K	Sell	36,262 -508	-1%	-$12.1K	0.84%	31
2024 Q1	$1.01M	Sell	36,770 -266	-0.7%	-$7.39K	1.02%	32
2023 Q4	$1.13M	Buy	+37,036	New	+$1.06M	1.25%	30

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Evolutionary Tree Capital Management's NTLA Position: Q1 2025 in Review

Evolutionary Tree Capital Management sold out of Intellia Therapeutics (NTLA) in Q1 2025, closing a stake of 47,406 shares — an estimated $553K sold.

Evolutionary Tree Capital Management first reported a position in NTLA in Q4 2023 and held it in 5 quarters. The position peaked at $1.13M in Q4 2023. 294 funds tracked by Wall St. Rank hold NTLA as of Q1 2025.

Evolutionary Tree Capital Management reported no remaining Intellia Therapeutics position as of Q1 2025 after selling out during the quarter.
Evolutionary Tree Capital Management sold 47,406 Intellia Therapeutics shares in Q1 2025, an estimated $553K.
Evolutionary Tree Capital Management first reported a position in Intellia Therapeutics in Q4 2023 and held it in 5 quarters.
Evolutionary Tree Capital Management's Intellia Therapeutics position peaked at $1.13M in Q4 2023.
294 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2025.

Based on Evolutionary Tree Capital Management's 13F filing for Q1 2025, filed 9 May 2025.